BR112022008223A2 - Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2 - Google Patents
Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2Info
- Publication number
- BR112022008223A2 BR112022008223A2 BR112022008223A BR112022008223A BR112022008223A2 BR 112022008223 A2 BR112022008223 A2 BR 112022008223A2 BR 112022008223 A BR112022008223 A BR 112022008223A BR 112022008223 A BR112022008223 A BR 112022008223A BR 112022008223 A2 BR112022008223 A2 BR 112022008223A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- mace
- prevention
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008223A2 true BR112022008223A2 (pt) | 2022-09-06 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008223A BR112022008223A2 (pt) | 2019-11-05 | 2020-11-04 | Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12551484B2 (https=) |
| EP (1) | EP4054584B1 (https=) |
| JP (1) | JP7502811B2 (https=) |
| KR (1) | KR102935008B1 (https=) |
| CN (1) | CN114650824A (https=) |
| AU (1) | AU2020377539B2 (https=) |
| BR (1) | BR112022008223A2 (https=) |
| CA (1) | CA3160147A1 (https=) |
| DK (1) | DK4054584T3 (https=) |
| ES (1) | ES3042146T3 (https=) |
| FI (1) | FI4054584T3 (https=) |
| HU (1) | HUE073043T2 (https=) |
| IL (1) | IL292696B1 (https=) |
| MX (1) | MX2022005029A (https=) |
| PL (1) | PL4054584T3 (https=) |
| PT (1) | PT4054584T (https=) |
| TW (1) | TWI867086B (https=) |
| WO (1) | WO2021090061A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| US20220370485A1 (en) * | 2021-01-14 | 2022-11-24 | Lexicon Pharmaceuticals, Inc. | Compounds and methods for treating or preventing cardiovascular diseases and conditions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| MX2011009852A (es) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| HK1219434A1 (zh) * | 2013-08-21 | 2017-04-07 | Resverlogix Corp. | 用於加速斑块消退的组合物和治疗方法 |
| AU2014310371A1 (en) | 2013-08-21 | 2016-03-10 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| EP3355922A2 (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
| EP3553058A1 (en) | 2016-12-09 | 2019-10-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| JP7763761B2 (ja) | 2020-01-08 | 2025-11-04 | レスバーロジックス コーポレイション | Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法 |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CA3197706A1 (en) | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
-
2020
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
- 2020-11-04 IL IL292696A patent/IL292696B1/en unknown
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220098757A (ko) | 2022-07-12 |
| IL292696B1 (en) | 2026-01-01 |
| EP4054584B1 (en) | 2025-07-09 |
| IL292696A (en) | 2022-07-01 |
| US20220370452A1 (en) | 2022-11-24 |
| HUE073043T2 (hu) | 2025-12-28 |
| MX2022005029A (es) | 2022-07-12 |
| TW202131924A (zh) | 2021-09-01 |
| AU2020377539A1 (en) | 2022-05-19 |
| CN114650824A (zh) | 2022-06-21 |
| ES3042146T3 (en) | 2025-11-18 |
| DK4054584T3 (en) | 2025-09-01 |
| FI4054584T3 (fi) | 2025-08-22 |
| CA3160147A1 (en) | 2021-05-14 |
| TWI867086B (zh) | 2024-12-21 |
| EP4054584A4 (en) | 2023-11-08 |
| EP4054584A1 (en) | 2022-09-14 |
| KR102935008B1 (ko) | 2026-03-09 |
| PT4054584T (pt) | 2025-07-16 |
| AU2020377539B2 (en) | 2025-05-29 |
| JP2023500685A (ja) | 2023-01-10 |
| PL4054584T3 (pl) | 2025-11-03 |
| WO2021090061A1 (en) | 2021-05-14 |
| US12551484B2 (en) | 2026-02-17 |
| JP7502811B2 (ja) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004332A (es) | Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos. | |
| BR112022008223A2 (pt) | Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2 | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| CL2020000860A1 (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. | |
| BR112022020291A2 (pt) | Inibidores de cd38 | |
| BR112013021236A2 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
| BR112015023448A2 (pt) | compostos e composições para o tratamento de doenças parasíticas | |
| AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| BR112022020814A2 (pt) | Métodos para tratamento de síndrome de liberação de citocina | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| BR112018071467A2 (pt) | método de tratamento ou prevenção de patologias hepáticas | |
| MX2020007152A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. | |
| BR112018016349A2 (pt) | métodos para tratamento e profilaxia de hiv e aids | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| BR112022018396A2 (pt) | Método de tratamento ou prevenção para insuficiência cardíaca crônica | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112018014957A2 (pt) | compostos e composições para o tratamento de criptosporidiose | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca |